Summary: A new study from King’s College London identifies a key cellular process affected by selective serotonin reuptake inhibitors (SSRIs) and highlights a promising application: using SSRIs to transiently increase blood-brain barrier permeability and improve delivery of other drugs to the brain. The researchers found that SSRIs alter membrane trafficking in many cell types, and that a single dose of fluvoxamine in mice allowed a normally excluded tracer to cross into the brain.
Since their introduction in the 1980s, SSRIs have been widely prescribed for depression and other mental health conditions. Despite their prevalence, the full range of biological actions for these medicines remains incompletely understood. This new research clarifies a cellular mechanism that appears to be commonly affected by SSRIs and explores how that mechanism could be leveraged for clinical use.
Key findings
- Commonly prescribed SSRIs influence membrane trafficking processes that control how cells internalize and release fluid and material.
- Laboratory tests at drug concentrations comparable to therapeutic blood levels showed that almost all tested antidepressants modulate fluid-phase uptake in cultured cells.
- A single injection of the SSRI fluvoxamine in mice enabled a fluorescent tracer—normally excluded from the brain—to accumulate inside the brain, demonstrating increased blood-brain barrier permeability in vivo.
- Molecular analyses indicate that fluvoxamine enhances clathrin-mediated endocytosis, alters the endosomal system and promotes exocytosis, while producing minimal changes in gene expression.
Study overview
Researchers tested currently prescribed SSRIs on a range of cell types grown in vitro, exposing the cells to concentrations similar to those seen in patients treated for depression. Across these experiments, most antidepressants modulated membrane trafficking—specifically the fluid-phase uptake that governs how cells take in extracellular fluid and dissolved molecules. This modulation was observed at therapeutic and lower concentrations, indicating that the effect may occur at clinically relevant doses.
Focusing on the SSRI fluvoxamine, the team characterized the trafficking changes in more detail. Fluvoxamine was found to increase clathrin-mediated endocytosis, expand activity within the endosomal network, and enhance exocytosis. RNA sequencing revealed very few transcriptional changes associated with fluvoxamine exposure, supporting the conclusion that the effects are largely post-transcriptional and not driven by altered gene expression.
To test whether these trafficking changes could alter delivery across the blood-brain barrier, the authors used cell-based models of the barrier and an in vivo mouse experiment. In cell models, increased membrane trafficking promoted transcytosis—the process by which substances are transported across endothelial cells that line blood vessels. In mice, a single fluvoxamine injection allowed a fluid-phase fluorescent tracer that normally remains outside the brain to accumulate within brain tissue, indicating a transient increase in blood-brain barrier permeability.
Implications and next steps
These findings suggest that modulation of membrane trafficking is a shared cellular action of many antidepressants and point to a potential repurposing opportunity: using SSRIs to transiently open the blood-brain barrier and improve delivery of therapeutic agents to the brain. That could have particular relevance for neurodegenerative conditions such as dementia, where many promising drugs struggle to reach effective concentrations in brain tissue.
The authors emphasize important caveats. The precise molecular mechanisms by which SSRIs influence membrane trafficking remain to be fully elucidated, and translating these results to humans will require careful clinical studies to establish safety, timing, dosage, and efficacy for drug delivery applications. Collaborative research across cell biology, pharmacology and clinical medicine will be needed to move from these preclinical findings to tested treatments.
If confirmed in humans, this work could expand the therapeutic uses of SSRIs beyond mood disorders and offer a new strategy for improving access of drugs to the brain. For now, the study identifies a conserved cellular response to antidepressants and opens a clear path for future investigation into medical repositioning of these well-established medications.
About this neuropharmacology research news
Author: Oleg Glebov
Source: King’s College London
Contact: Oleg Glebov – King’s College London
Image: The image is credited to Neuroscience News
Original Research: Open access. “Antidepressant-induced membrane trafficking regulates blood-brain barrier permeability” by Oleg Glebov et al., published in Molecular Psychiatry.
Abstract
Antidepressant-induced membrane trafficking regulates blood-brain barrier permeability
Antidepressant drugs (ADs) of the selective serotonin reuptake inhibitor (SSRI) class are among the most widely prescribed psychotropic medicines, making them strong candidates for drug repurposing. The mechanisms behind their actions remain incompletely defined. This study demonstrates that common SSRIs and selected representatives of other antidepressant classes bidirectionally regulate fluid-phase uptake at therapeutic concentrations and below. Characterization of fluvoxamine-induced membrane trafficking shows enhanced clathrin-mediated endocytosis, modulation of the endosomal system, and increased exocytosis. RNA sequencing revealed few expression changes, consistent with an effect largely independent of gene transcription. Fluvoxamine increased transcytosis in cell-based blood-brain barrier models, and a single in vivo injection enabled brain accumulation of a fluid-phase fluorescent tracer. These results identify modulation of membrane trafficking by antidepressants as a potential cellular mechanism of action and suggest their clinical repositioning potential for regulating drug delivery to the brain.